Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic
Anemia is a frequent manifestation in patients with chronic inflammatory bowel disease (IBD) and requires tight monitoring and adequate supplementary therapy. Intravenous iron is the first-line treatment in subjects with moderate–severe anemia, active disease, or oral iron intolerance. On the other...
Main Authors: | Ferdinando D’Amico, Laurent Peyrin-Biroulet, Silvio Danese |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/5/1536 |
Similar Items
-
Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment
by: Guillermo Bastida, et al.
Published: (2021-05-01) -
Iron Deficiency Anemia in Inflammatory Bowel Disease: What Do We Know?
by: Tamás Resál, et al.
Published: (2021-07-01) -
Risk-Benefit of IBD Drugs: A Physicians and Patients Survey
by: Ferdinando D’Amico, et al.
Published: (2023-04-01) -
Oral iron versus intravenous iron therapy in moderate iron deficiency anemia in pregnancy
by: Hussain Md Shohail, et al.
Published: (2023-08-01) -
Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials
by: Ferdinando D'Amico, et al.
Published: (2020-07-01)